Since dual blockade of CTLA-4 and PD-1 induced responses similar to chemotherapy in these soft tissue sarcomas, combinatory immunotherapy is being further explored in the clinic (https://clinicaltrials.gov/ Identifiers: NCT04741438; NCT04480502; NCT02500797. The gene discussed is CTLA4; the disease is soft tissue sarcoma.